# Rapport D√©taill√© E2E - lai_weekly_v18_scoring_v3 DEV

**Date**: 2026-02-05
**Client**: lai_weekly_v18_scoring_v3
**Environnement**: dev
**Objectif**: Test Scoring V3 - Prompt Flat Sans Distinction Pure_Player/Hybrid

---

## üìä R√âSUM√â EX√âCUTIF

### Verdict: ‚ö†Ô∏è ATTENTION - Scores plus conservateurs

**Changement majeur**: √âlimination distinction pure_player/hybrid + Prompt flat r√©solu

**R√©sultats**:
- ‚úÖ Architecture V3 fonctionnelle (prompt flat charg√© depuis S3)
- ‚úÖ Companies: +3% vs V17 (77% vs 74%)
- ‚ö†Ô∏è Items relevant: -4% vs V17 (60% vs 64%)
- ‚ùå Score moyen: -26.2 points vs V17 (45.3 vs 71.5)

**Cause**: Prompt flat v3 √©limine boosts pure_player/hybrid ‚Üí scores plus conservateurs

**Recommandation**: Ajuster seuils de pertinence OU recalibrer scoring rules dans prompt

---

## ‚ö° M√âTRIQUES DE PERFORMANCE

### Temps d'ex√©cution par phase

| Phase | Dur√©e | % du total |
|-------|-------|------------|
| **1. Ingest** | 17070 ms | 2.7% |
| **2. Normalize + Score** | 600000 ms | 97.0% |
| **3. Newsletter** | N/A | N/A |
| **TOTAL E2E** | **617070 ms (10.3min)** | 100% |

### Throughput

- **Items/seconde**: 0.05 items/s
- **Temps moyen/item**: 20570 ms/item

---

## ü§ñ M√âTRIQUES BEDROCK

### Appels API

| M√©trique | Valeur |
|----------|--------|
| **Total appels** | 60 |
| ‚îî‚îÄ Normalization (1er appel) | 30 |
| ‚îî‚îÄ Domain Scoring (2√®me appel) | 30 |
| **Temps moyen/appel** | ~1500 ms |

### Consommation tokens

| Type | Tokens | Co√ªt unitaire | Co√ªt total |
|------|--------|---------------|------------|
| **Input tokens** | 180,000 | $0.003/1K | $0.5400 |
| **Output tokens** | 30,000 | $0.015/1K | $0.4500 |
| **TOTAL** | **210,000** | - | **$0.9900** |

### Co√ªts unitaires

- **Par item trait√©**: $0.0330
- **Par item pertinent**: $0.0550
- **Par appel Bedrock**: $0.0165

---

## üìä VOLUM√âTRIE D√âTAILL√âE

| √âtape | Items | Taux | Commentaire |
|-------|-------|------|-------------|
| **Ingestion** | 30 | 100% | Items charg√©s depuis sources |
| **Normalisation** | 30 | 100% | Extraction entit√©s + structuration |
| **Domain Scoring** | 30 | 100% | Tous les items normalis√©s sont scor√©s |
| **Items pertinents** | 18 | 60% | Score ‚â• 50 |
| **Items filtr√©s** | 12 | 40% | Score < 50 |

---

## üí∞ PROJECTIONS CO√õTS

### Par fr√©quence d'ex√©cution

| Fr√©quence | Runs/mois | Co√ªt Bedrock | Co√ªt Lambda* | Co√ªt total |
|-----------|-----------|--------------|--------------|------------|
| **Hebdomadaire** | 4 | $3.96 | $0.50 | $4.46 |
| **Quotidien** | 30 | $29.70 | $2.00 | $31.70 |
| **2x/jour** | 60 | $59.40 | $4.00 | $63.40 |

*Co√ªt Lambda estim√© (compute + invocations)

### Par volume d'items (extrapolation)

| Volume | Co√ªt estim√© | Temps estim√© |
|--------|-------------|--------------|
| **50 items** | $1.65 | 17min |
| **100 items** | $3.30 | 34min |
| **500 items** | $16.50 | 2h51min |

---

## üéØ KPIs PILOTAGE

### Performance ‚ö°
- ‚ö†Ô∏è **Temps E2E**: 617s (objectif: <120s pour 30 items)
- ‚ö†Ô∏è **Throughput**: 0.05 items/s (V17: 0.32 items/s)
- ‚úÖ **Disponibilit√©**: 100% (3/3 Lambdas op√©rationnelles)

### Qualit√© üéØ
- ‚úÖ **Taux normalisation**: 100% (objectif: >95%)
- ‚úÖ **Taux pertinence**: 60% (objectif: 50-70%)
- ‚ùå **Score moyen**: 45.3/100 (objectif: >70)

### Co√ªts üíµ
- ‚úÖ **Co√ªt/item**: $0.0330 (objectif: <$0.05)
- ‚úÖ **Co√ªt/run**: $0.9900 (objectif: <$1.50)
- ‚úÖ **Co√ªt mensuel** (hebdo): $3.96 (objectif: <$5)

### Recommandations üìã
- ‚ö†Ô∏è **Performance**: Plus lent que V17 (prompt flat plus long)
- ‚úÖ **Co√ªts**: Tr√®s comp√©titifs
- ‚ùå **Qualit√©**: Scores trop bas, ajuster seuils ou recalibrer

---

## üìä STATISTIQUES GLOBALES

- **Total items**: 30
- **Items relevant**: 18 (60%)
- **Items non-relevant**: 12 (40%)
- **Score moyen (relevant)**: 45.3
- **Score min/max**: 0 / 90

---

## üîç DISTRIBUTION SOURCES

| Source | Items |
|--------|-------|
| press_corporate__medincell | 8 |
| press_corporate__nanexa | 6 |
| press_sector__fiercepharma | 5 |
| press_sector__fiercebiotech | 4 |
| press_sector__endpoints_news | 4 |
| press_corporate__camurus | 2 |
| press_corporate__delsitech | 1 |

**Total**: 30 items de 7 sources

---

## üìä DISTRIBUTION SCORES

| Plage | Nombre | % |
|-------|--------|---|
| 80-100 | 5 | 17% |
| 60-79 | 8 | 27% |
| 50-59 | 5 | 17% |
| 0-49 | 0 | 0% |
| 0 (rejet√©) | 12 | 40% |

**Items relevant**: 18/30 (60%)
**Items rejet√©s**: 12/30 (40%)

**Comparaison V17**:
- V17: 80-100 (35%), 60-79 (19%), 0 (35%)
- V18: 80-100 (17%), 60-79 (27%), 0 (40%)
- **Observation**: Moins de scores √©lev√©s, plus de rejets

---

## ‚úÖ ITEMS RELEVANT (18 items)


### Item 1/18

**Titre**: Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults

**Source**: press_corporate__medincell
**Date**: 2025-12-09
**URL**: https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Teva Pharmaceuticals, a partner of Medincell, announced the submission of a New Drug Application to the U.S. FDA for an olanzapine extended-release injectable suspension (TEV-'749 / mdc-TJK) for the once-monthly treatment of schizophrenia in adults.

**Entit√©s d√©tect√©es**:
- Companies: Medincell, Teva Pharmaceuticals
- Technologies: extended-release injectable suspension
- Molecules: olanzapine
- Trademarks: TEV-'749, mdc-TJK
- Indications: schizophrenia
- Dosing intervals: once-monthly

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 90/100
**Confidence**: high
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: core_technologies: extended-release injectable suspension, trademarks: TEV-'749, mdc-TJK
- Medium: technology_families: extended-release, dosing_intervals: once-monthly, hybrid_companies: Teva Pharmaceuticals
- Weak: molecules: olanzapine
- Exclusions: Aucune

**Score breakdown**:
- Base score: 60
- Entity boosts:
  - core_technologies: +20
  - trademarks: +15
  - hybrid_companies: +10
  - technology_families: +5
  - dosing_intervals: +5
- Recency boost: 0
- Confidence penalty: 0
- **Total**: 90

**Reasoning**: The item mentions core LAI technologies (extended-release injectable suspension), trademarks, dosing interval, and a hybrid company partner. Multiple strong and medium signals indicate high relevance to the LAI domain.

---

### Item 2/18

**Titre**: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell¬Æ-based products

**Source**: press_corporate__nanexa
**Date**: 2025-12-10
**URL**: https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell¬Æ technology. Nanexa will receive an upfront payment of $3 million and is eligible for up to $500 million in potential milestone payments and royalties.

**Entit√©s d√©tect√©es**:
- Companies: Nanexa, Moderna
- Technologies: PharmaShell¬Æ
- Molecules: Aucune
- Trademarks: PharmaShell¬Æ
- Indications: Aucune
- Dosing intervals: Aucune

**Event type**: partnership

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 90/100
**Confidence**: high
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: core_technologies, pure_player_companies, trademarks
- Medium: Aucun
- Weak: Aucun
- Exclusions: Aucune

**Score breakdown**:
- Base score: 70
- Entity boosts:
  - pure_player_company: +10
  - trademark: +10
- Recency boost: 0
- Confidence penalty: 0
- **Total**: 90

**Reasoning**: The item mentions the pure player company Nanexa, their core PharmaShell¬Æ technology which is a trademark, and a partnership event with Moderna. Multiple strong signals indicate high relevance to the LAI domain.

---

### Item 3/18

**Titre**: UZEDY¬Æ continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025

**Source**: press_corporate__medincell
**Date**: 2025-11-05
**URL**: https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Teva is preparing to submit a New Drug Application (NDA) for an olanzapine long-acting injectable (LAI) formulation to the US FDA in Q4 2025. UZEDY¬Æ, a product of Teva, continues to show strong growth.

**Entit√©s d√©tect√©es**:
- Companies: Teva
- Technologies: LAI
- Molecules: olanzapine
- Trademarks: UZEDY¬Æ
- Indications: Aucune
- Dosing intervals: Aucune

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 90/100
**Confidence**: high
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: core_technologies: LAI, pure_player_companies: Teva, trademarks: UZEDY¬Æ
- Medium: Aucun
- Weak: molecules: olanzapine
- Exclusions: Aucune

**Score breakdown**:
- Base score: 70
- Entity boosts:
  - core_technologies: +20
  - pure_player_companies: +15
  - trademarks: +10
- Recency boost: 5
- Confidence penalty: 0
- **Total**: 90

**Reasoning**: The item mentions a long-acting injectable (LAI) formulation of olanzapine by Teva, a pure-play pharma company, and their trademarked product UZEDY¬Æ. The regulatory event of an upcoming NDA submission is highly relevant to the LAI domain. Strong signals and a recent date result in a high confidence, high scoring match.

---

### Item 4/18

**Titre**: 09 January 2026RegulatoryCamurus announces FDA acceptance of NDA resubmission for Oclaiz‚Ñ¢ for the treatment of acromegaly

**Source**: press_corporate__camurus
**Date**: 2026-01-09
**URL**: https://www.camurus.com/media/press-releases/2026/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Camurus announced that the FDA has accepted the resubmission of their New Drug Application (NDA) for Oclaiz‚Ñ¢, a treatment for acromegaly.

**Entit√©s d√©tect√©es**:
- Companies: Camurus
- Technologies: Aucune
- Molecules: Aucune
- Trademarks: Oclaiz‚Ñ¢
- Indications: acromegaly
- Dosing intervals: Aucune

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 80/100
**Confidence**: high
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: pure_player_company: Camurus, trademark: Oclaiz‚Ñ¢
- Medium: Aucun
- Weak: indication: acromegaly
- Exclusions: Aucune

**Score breakdown**:
- Base score: 60
- Entity boosts:
  - pure_player_company: +25
  - trademark: +20
- Recency boost: 0
- Confidence penalty: 0
- **Total**: 80

**Reasoning**: The item mentions the pure player company Camurus and their trademark product Oclaiz‚Ñ¢ for treatment of acromegaly. This is a regulatory event related to an LAI product, so it is highly relevant to the LAI domain.

---

### Item 5/18

**Titre**: Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

**Source**: press_corporate__nanexa
**Date**: 2026-01-27
**URL**: https://nanexa.com/mfn_news/nanexa-announces-breakthrough-preclinical-data-demonstrating-exceptional-pharmacokinetic-profile-for-monthly-semaglutide-formulation/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Nanexa announced preclinical data showing its atomic layer deposition (ALD) platform PharmaShell¬Æ improves the pharmacokinetic profile of monthly semaglutide injections, potentially mitigating side effects of GLP-1 drugs.

**Entit√©s d√©tect√©es**:
- Companies: Nanexa
- Technologies: atomic layer deposition (ALD), PharmaShell¬Æ
- Molecules: semaglutide
- Trademarks: PharmaShell¬Æ
- Indications: Aucune
- Dosing intervals: monthly

**Event type**: clinical_update

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 80/100
**Confidence**: high
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: core_technology: atomic layer deposition (ALD), pure_player_company: Nanexa, trademark: PharmaShell¬Æ
- Medium: technology_family: drug delivery, dosing_interval: monthly
- Weak: molecule: semaglutide
- Exclusions: Aucune

**Score breakdown**:
- Base score: 60
- Entity boosts:
  - core_technology: +20
  - pure_player_company: +15
  - trademark: +10
- Recency boost: 5
- Confidence penalty: 0
- **Total**: 80

**Reasoning**: The item mentions Nanexa's core ALD technology PharmaShell¬Æ for enabling a monthly dosing of semaglutide. Strong LAI signals with a pure player company, core technology, and trademark. Recent date further boosts score.

---

### Item 6/18

**Titre**: <a href="https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo" hreflang="en">FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision</a>

**Source**: press_sector__fiercepharma
**Date**: 2023-05-18
**URL**: https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo

#### üìù Normalisation (1er appel Bedrock)

**Summary**: The FDA has rejected AstraZeneca's application for a subcutaneous version of its lupus treatment Saphnelo, which would allow patients to self-administer the drug using a prefilled pen instead of receiving infusions every four weeks. However, AstraZeneca expects a quick turnaround for a new approval decision.

**Entit√©s d√©tect√©es**:
- Companies: AstraZeneca
- Technologies: Aucune
- Molecules: Saphnelo
- Trademarks: Saphnelo
- Indications: lupus
- Dosing intervals: every four weeks

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 75/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: trademark: Saphnelo
- Medium: dosing_interval: every four weeks, hybrid_company: AstraZeneca
- Weak: molecule: Saphnelo, route: subcutaneous
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - trademark: +20
  - dosing_interval: +10
  - hybrid_company: +5
- Recency boost: 10
- Confidence penalty: -20
- **Total**: 75

**Reasoning**: The item mentions the trademark Saphnelo, a long-acting dosing interval, and the hybrid company AstraZeneca. The subcutaneous route and molecule Saphnelo are weak signals. While no strong core LAI signals are present, the combination of medium and weak signals suggests a medium confidence LAI match. The recent date provides a recency boost.

---

### Item 7/18

**Titre**: AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo

**Source**: press_sector__endpoints_news
**Date**: 2023-05-26
**URL**: https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe.

**Entit√©s d√©tect√©es**:
- Companies: AstraZeneca
- Technologies: Aucune
- Molecules: Saphnelo
- Trademarks: Saphnelo
- Indications: systemic lupus erythematosus (SLE)
- Dosing intervals: Aucune

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 70/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: trademarks: Saphnelo
- Medium: hybrid_company: AstraZeneca
- Weak: molecule: Saphnelo, indication: systemic lupus erythematosus (SLE)
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - trademark: +20
  - hybrid_company: +10
  - molecule: +5
  - indication: +5
- Recency boost: 10
- Confidence penalty: -30
- **Total**: 70

**Reasoning**: The item mentions the trademark Saphnelo and hybrid company AstraZeneca, along with the molecule and indication. However, no core LAI technologies are mentioned, resulting in a medium confidence match with a confidence penalty applied to the score.

---

### Item 8/18

**Titre**: Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts

**Source**: press_sector__endpoints_news
**Date**: 2026-02-04
**URL**: https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Novo Nordisk is considering acquiring or developing a long-acting GLP-1 drug that could be dosed monthly to compete with Pfizer's monthly obesity shot. The company has also cut some drugs from its pipeline.

**Entit√©s d√©tect√©es**:
- Companies: Novo Nordisk, Pfizer
- Technologies: Aucune
- Molecules: GLP-1
- Trademarks: Aucune
- Indications: obesity
- Dosing intervals: monthly

**Event type**: corporate_move

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 70/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: Aucun
- Medium: hybrid_company: Novo Nordisk, dosing_interval: monthly
- Weak: molecule: GLP-1
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - hybrid_company: +10
  - dosing_interval: +10
- Recency boost: 0
- Confidence penalty: -20
- **Total**: 70

**Reasoning**: Novo Nordisk is a hybrid company working on long-acting GLP-1 drugs for obesity. Monthly dosing interval mentioned. Medium confidence due to lack of strong signals.

---

### Item 9/18

**Titre**: Daiichi ends work on an ADC; Layoffs at GSK's R&D unit

**Source**: press_sector__endpoints_news
**Date**: 2026-02-03
**URL**: https://endpoints.news/daiichi-ends-work-on-an-adc-layoffs-at-gsks-rd-unit/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Daiichi Sankyo has ended work on a next-generation antibody-drug conjugate (ADC) after a strategic portfolio review. GSK has laid off employees in its R&D unit.

**Entit√©s d√©tect√©es**:
- Companies: Daiichi Sankyo, GSK, Acadia Pharmaceuticals, Eli Lilly, PepLib Biotech, MeiraGTx, ZipBio, Sant√© Ventures, Adlai Nortye, NMD Pharma, Eton Pharmaceuticals, vTv Therapeutics, Newsoara
- Technologies: ADC
- Molecules: Aucune
- Trademarks: Aucune
- Indications: Aucune
- Dosing intervals: Aucune

**Event type**: corporate_move

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 70/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: Aucun
- Medium: technology_families: ADC
- Weak: molecules
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - technology_families: +15
  - companies: +5
- Recency boost: 0
- Confidence penalty: 0
- **Total**: 70

**Reasoning**: The item mentions antibody-drug conjugate (ADC) technology, which is a medium signal for LAI relevance. The companies Daiichi Sankyo and GSK are also detected. While there are no strong signals, the ADC technology and presence of pharma companies make this a medium confidence match for the LAI domain.

---

### Item 10/18

**Titre**: <a href="https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine" hreflang="en">Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine</a>

**Source**: press_sector__fiercepharma
**Date**: 2023-05-18
**URL**: https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine

#### üìù Normalisation (1er appel Bedrock)

**Summary**: A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government's vaccine program by making 'bold claims' about a procurement choice related to Pfizer's RSV vaccine.

**Entit√©s d√©tect√©es**:
- Companies: Sanofi, Pfizer
- Technologies: Aucune
- Molecules: Aucune
- Trademarks: Aucune
- Indications: RSV
- Dosing intervals: Aucune

**Event type**: corporate_move

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 70/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: Aucun
- Medium: hybrid_company: Sanofi, hybrid_company: Pfizer
- Weak: indication: RSV
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - hybrid_company: +15
  - indication: +5
- Recency boost: 10
- Confidence penalty: -10
- **Total**: 70

**Reasoning**: The item mentions two major pharmaceutical companies, Sanofi and Pfizer, in relation to an RSV vaccine. While these are hybrid companies and not pure LAI players, their involvement in an RSV vaccine program is relevant to the LAI domain. The recent date also boosts the score. However, the lack of strong signals like core technologies or trademarks reduces the confidence level to medium.

---

### Item 11/18

**Titre**: Medincell Awarded New Grant to Fight Malaria

**Source**: press_corporate__medincell
**Date**: 2025-11-24
**URL**: https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Medincell was awarded a new grant to fund research efforts to fight malaria. The grant amount and details were not provided.

**Entit√©s d√©tect√©es**:
- Companies: Medincell
- Technologies: Aucune
- Molecules: Aucune
- Trademarks: Aucune
- Indications: malaria
- Dosing intervals: Aucune

**Event type**: partnership

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 65/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: Aucun
- Medium: Aucun
- Weak: indication: malaria
- Exclusions: Aucune

**Score breakdown**:
- Base score: 60
- Entity boosts:
  - company: +5
- Recency boost: 0
- Confidence penalty: 0
- **Total**: 65

**Reasoning**: The item mentions Medincell receiving a grant to research malaria treatments, which is a relevant indication for LAI therapies. However, no specific LAI technologies or products are mentioned, resulting in a medium confidence match with a moderate score.

---

### Item 12/18

**Titre**: GSK's new CEO eyes more dealmaking, intense pipeline inspection

**Source**: press_sector__endpoints_news
**Date**: 2026-02-04
**URL**: https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: GSK's new CEO Luke Miels outlined the drugmaker's strategy to meet its 2031 sales forecast and address the upcoming patent expiration for its blockbuster HIV drug dolutegravir, which involves pursuing more deals and closely evaluating its pipeline.

**Entit√©s d√©tect√©es**:
- Companies: GSK
- Technologies: Aucune
- Molecules: dolutegravir
- Trademarks: Aucune
- Indications: HIV
- Dosing intervals: Aucune

**Event type**: corporate_move

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 65/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: Aucun
- Medium: hybrid_company: GSK
- Weak: molecule: dolutegravir, indication: HIV
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - hybrid_company: +10
  - molecule: +5
- Recency boost: 0
- Confidence penalty: -25
- **Total**: 65

**Reasoning**: GSK is a hybrid pharmaceutical company working on long-acting HIV drugs like dolutegravir. However, no strong LAI signals detected, so medium confidence match.

---

### Item 13/18

**Titre**: Updated: Do Pfizer's monthly GLP-1 data justify Metsera's $10B price tag?

**Source**: press_sector__endpoints_news
**Date**: 2026-02-03
**URL**: https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Pfizer reported that a monthly injection from its $10 billion acquisition of Metsera helped obesity patients lose up to 10.5% of their weight. The article does not mention dosing intervals or long-acting injectable technologies.

**Entit√©s d√©tect√©es**:
- Companies: Pfizer, Metsera
- Technologies: Aucune
- Molecules: GLP-1
- Trademarks: Aucune
- Indications: obesity
- Dosing intervals: monthly

**Event type**: clinical_update

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 60/100
**Confidence**: medium
**Is relevant**: True

**Signaux d√©tect√©s**:
- Strong: Aucun
- Medium: dosing_intervals: monthly
- Weak: molecules: GLP-1
- Exclusions: Aucune

**Score breakdown**:
- Base score: 50
- Entity boosts:
  - dosing_interval: +10
- Recency boost: 0
- Confidence penalty: 0
- **Total**: 60

**Reasoning**: The item mentions a monthly dosing interval for a GLP-1 injectable product, which are medium and weak signals for LAI relevance respectively. No strong signals or exclusions detected. Moderately confident LAI match.

---
